Portfolio

  • Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation

    November 5, 2018

    COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its lead compound in cardioversion, AP30663. The results of the study demonstrated that intravenous AP30663 was well tolerated with ascending doses, with no significant adverse events.  Link to Press Release

    Read More
  • AtaCor Medical Raises $8.8M to Develop Substernal Cardiac Pacing System

    September 18, 2018

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (www.atacor.com) announced today that it has completed a $8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-based aMoon Ventures, the financing also includes participation from a corporate partner. The investment will support the continued development of AtaCor’s revolutionary extravascular substernal cardiac pacing system. Link to Press Release

    Read More
  • Aeromics Initiates Phase 1 Clinical Trial of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers

    July 10, 2018

    BRANFORD, Conn., July 9, 2018 /PRNewswire/ -- Aeromics, Inc. ("Aeromics" or "the Company"), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic stroke, announced today the initiation of a Phase 1 clinical trial in healthy volunteers of its first-in-class drug candidate, AER-271. Link to Press Release

    Read More
  • CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC Device

    May 17, 2018

    TORONTO, Canada, May 17, 2018 – CellAegis Devices Inc. (“CellAegis” or the “Company”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored trial (“CONDI 2”) to further assess the efficacy of remote ischemic conditioning (“RIC”) in reducing clinical events in patients presenting with ST-segment-elevation myocardial infarction (“STEMI”) and receiving point of care treatment by pa

    Read More
  • CellAegis to complete enrollment in U.S. autoRIC trial by end of 2018

    May 8, 2018

    In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its own U.S. pivotal trial for the treatment of elective percutaneous coronary intervention (ePCI) to complete enrolment before the end of 2018. Link to Press Release

    Read More
  • VGS Initiates U.S. Pivotal Trial to Evaluate the Use of Its VEST Technology for Bypass Surgery

    April 23, 2018

    TEL AVIV, Israel, April 23, 2018 /PRNewswire/ -- Vascular Graft Solutions Ltd (VGS) announces on enrollment of the first 20 patients into the VEST US pivotal trial that will evaluate the safety and effectiveness of the VEST, a novel external support device for treatment of saphenous vein graft disease after coronary artery bypass grafting (CABG). "After more than 1,000 successful implantations in Europe, we are excited to achieve this important milestone and begin our pivotal trial in the U.S." said Eyal Orion, founder and CEO of VGS. Link to Press Release

    Read More
  • Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema

    April 16, 2018

    Herantis Pharma PlcCompany release 16 Apr 2018 at 9:00 am Herantis Pharma Plc (“Herantis”) announced today positive results from a safety evaluation in the ongoing Phase 1 clinical study assessing the safety and tolerability of the company’s investigational gene therapy product Lymfactin® in the treatment of secondary lymphedema. Based on data from all 15 patients recruited, the study’s Data Monitoring Committee (“DMC”) of independent experts concluded that Lymfactin® continues to appear safe and well tolerated. No dose limiting toxicities were observed. The safety evaluation wa

    Read More
  • CellAegis Announces First Patients Enrolled in U.S. Shield Pivotal Clinical Trial

    April 10, 2018

    TORONTO, Canada, April 10, 2018 (GLOBE NEWSWIRE) – CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced enrollment of the first patients in a U.S. clinical trial (“SHIELD”) of its autoRIC® device. The autoRIC® device automatically delivers remote ischemic conditioning (“RIC”) to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardio

    Read More
  • Broadview Ventures 2017 Annual Report

    March 20, 2018

    Broadview Ventures 2017 Annual Report

    Read More
  • Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation

    March 12, 2018

    COPENHAGEN, Denmark— 12 March 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces it has commenced the clinical study for its lead compound AP30663. Acesion is developing a portfolio of drugs addressing both paroxysmal (acute) and persistent AF. Link to Press Release

    Read More